Research Ethics and Integrity

Medical research rests on a social licence: participants expose themselves to risk so that future patients may benefit. Research ethics is the body of principle and law that keeps that licence trustworthy. It does three things at once. It protects the participant from harm and exploitation, it protects the integrity of the knowledge produced, and it protects the researcher and the institution from the legal, professional and reputational consequences of a breach.

Three reasons make this a regular examiner topic rather than a box to tick. First, the historical disasters that created the field — wartime experimentation, the Tuskegee study, retention of organs without consent — were failures of judgement by otherwise competent doctors, so examiners test whether you can recognise the principles, not just recite the names. Second, the duties are concrete and operational: every surgeon who runs a registry, audits an implant, or co-authors a paper is already inside this framework whether they realise it or not. Third, the penalties are severe and public — retraction, deregistration, loss of funding, referral to the regulator and, in some jurisdictions, criminal liability — so a wrong answer signals an unsafe practitioner.

The governing idea across every code is the same: the well-being of the individual participant takes precedence over all other interests, including the interests of science and society. Every principle, approval and consent process below is a mechanism for enforcing that one idea.

Examiners look for a structured answer, and the cleanest frame is the chronological ladder of codes. Each was a direct response to a scandal, and together they harden the same core idea into progressively enforceable rules.

1. Nuremberg Code (1947) — drawn from the judgement at the Doctors' Trial. Its first article makes the voluntary, informed consent of the participant "absolutely essential", and sets out that the experiment must be for the good of society, avoid unnecessary suffering, and be stoppable. It is the cornerstone of modern consent.
2. Declaration of Helsinki (1964) — the World Medical Association's ethical principles for medical research involving human participants. It is the document research ethics committees actually apply. It requires independent ethics review, a favourable risk-benefit balance, special protection for vulnerable groups, and the participant's right to withdraw. Adopted in 1964, it is revised periodically, most recently in 2024.
3. Belmont Report (1979) — the US National Commission distilled research ethics into three principles: respect for persons, beneficence, and justice. It underpins the US "Common Rule" and is the cleanest three-word summary an examiner will accept.
4. CIOMS International Ethical Guidelines (2002, revised 2016) — extends these principles to research in low-resource settings and to research involving identifiable data and biological materials.
5. National law and good clinical practice — ICH-GCP for trials, the US Common Rule, the UK Health Research Authority and Research Ethics Committees, and the Australian NHMRC National Statement administered by Human Research Ethics Committees. The mechanisms differ; the Helsinki principles do not.

The dominant framework in day-to-day clinical and research ethics is the four-principles approach of Beauchamp and Childress, set out in their Principles of Biomedical Ethics. It is not a decision algorithm, but a shared vocabulary for naming the values in conflict, which is what an examiner wants to see you do.

A concept that examiners reach for specifically in trial ethics is equipoise. It is the honest, genuine uncertainty within the expert community about which of two treatments is better. Charles Fried framed the problem in 1974, and Benjamin Freedman refined it in 1987 into "clinical equipoise": randomisation is ethically permissible only while the community of competent practitioners is collectively undecided.

This matters because it answers the common objection "how can a doctor randomly assign a patient?" The answer is that the doctor is not choosing arbitrarily — they are entering the patient at a moment when no one yet knows which arm is superior, and the trial is the means of resolving that uncertainty. Equipoise is disturbed the moment a treatment proves superior, which is why trials have stopping rules and data-monitoring committees, and why continuing to enrol once the question is answered is itself unethical.

Before any participant is approached, the protocol must be reviewed and approved by an independent committee — an Institutional Review Board in the United States or a Research Ethics Committee elsewhere. The committee tests three things: whether the risk-benefit balance is favourable, whether the selection of participants is fair, and whether the consent process is adequate. Approval is a precondition, not a courtesy, and it covers the protocol, the participant information sheet, the consent form, and any later amendment.

A frequent practical and exam question is where the boundary between research, clinical audit and service evaluation lies, because it determines whether ethics approval is needed at all.

The border is not always clean. A quality project that prospectively assigns patients to different pathways, or that uses data in a way patients would not have expected, has crossed into research and needs approval. When there is genuine doubt the correct action is to ask the committee in writing, not to proceed and argue afterwards — the duty is to the participant and the integrity of the record, not to the timeline.

Consent in research is not a signature, it is a process, and it is held to a higher standard than clinical consent because the participant may derive no personal benefit. Five elements must all be present: the participant must have capacity, must receive adequate information, must comprehend that information, must decide voluntarily without coercion or undue influence, and must give specific consent to the research in question.

The information disclosed must include the purpose of the study, the procedures and their alternatives, the foreseeable risks and discomforts, the absence of guaranteed benefit, the right to withdraw without any penalty to ongoing care, and the handling of data. A recurring trap is therapeutic misconception — the participant wrongly believing that the trial is individualised treatment chosen for their benefit. The researcher must correct this explicitly, because a consent built on a misunderstanding is not valid consent.

The standard for what counts as adequate disclosure in consent law has itself moved, and examiners expect the case-law ladder.

The practical effect of Montgomery is that risk disclosure is now judged from the patient's perspective, not the doctor's. In research this reinforces the duty: a trial participant must be told everything a reasonable person in their position would consider significant, including the uncertainty that justifies the trial in the first place.

Vulnerable participants — children, adults lacking capacity, pregnant women, prisoners, and patients in emergency or intensive-care settings — require additional safeguards. Consent may need to be obtained from a legally authorised representative, with assent from the participant where possible, and the study must be one that cannot equally be done in a non-vulnerable group.

Research integrity is the positive duty to conduct, record and report work honestly. Research misconduct is the deliberate breach of that duty. The widely used definition, from the US Office of Research Integrity, centres on three acts, known as FFP: fabrication, falsification, and plagiarism.

A large and damaging grey zone surrounds these — the questionable research practices that fall short of formal misconduct but corrode the record: salami-slicing one study into several papers, selective reporting of outcomes, p-hacking, image manipulation, ghost and gift authorship, and failing to publish negative results. The Singapore Statement on Research Integrity (2010) addressed exactly this by setting four principles for the whole conduct of research: honesty, accountability, professional courtesy and fairness, and good stewardship.

What you must do when you suspect misconduct is the part examiners most often probe, and the answer is a process, not a confrontation.

Authorship is a statement of responsibility, both credit and accountability, and it is governed by the International Committee of Medical Journal Editors (ICMJE) Recommendations. To be listed as an author a contributor must meet all four criteria — there is no half-measure.

The four criteria are: substantial contribution to the conception or design, or to data acquisition, analysis or interpretation; AND drafting or critically revising the work for important intellectual content; AND final approval of the version to be published; AND agreement to be accountable for all aspects of the work. 4all required Contributors who fall short of all four — for example providing funding, collecting data without intellectual input, or general supervision — belong in the Acknowledgements, with their consent, not on the author list.

Two recurring abuses are explicitly misconduct. Gift or honorary authorship adds a senior name who did not meet the criteria to lend credibility. Ghost authorship hides a real contributor, often a writer funded by industry, from the byline. Both distort the record of who is accountable, and both are condemned by the ICMJE and by the Committee on Publication Ethics.

Beyond the byline, four further duties apply. Clinical trials must be publicly registered before the first participant is enrolled, in a recognised registry such as ClinicalTrials.gov, with reporting of results. Reporting guidelines must be followed: CONSORT for randomised trials, PRISMA for systematic reviews, STROBE for observational studies, and CARE for case reports. Conflicts of interest, financial and non-financial, must be disclosed at submission, because undisclosed conflict is a common cause of retraction. And when published work is wrong, the duty is to correct it — by a correction or erratum for an honest error, by a retraction for serious flaws or misconduct, never by silent deletion.

One point that has hardened in the last few years: artificial-intelligence and large-language-model tools cannot be authors, because they cannot take responsibility, and their use in writing or analysis must be disclosed. Using them to generate text without declaration is a breach of the same integrity duty.

Research ethics and patient safety share an underlying idea that examiners reward: most failures are produced by systems, not by a single bad person, and integrity is sustained by design rather than willpower. James Reason's model of accident causation pictures defences against failure as slices of Swiss cheese, each with holes; a harm reaches the patient only when the holes line up. The lesson for integrity is that the robust response is to build layers — independent review, dual data entry, trial registration, open data, conflict declaration — rather than to rely on individual honesty alone.

The clearest demonstration in surgery that a system-level intervention, tested by research, saves lives is the WHO Surgical Safety Checklist. The global study by Haynes and colleagues reported a fall in death from 1.5 to 0.8 per cent and in complications from 11 to 7 per cent after checklist implementation — roughly a ~47%lower death rate relative reduction. It is included here because it shows the whole loop the exam topic sits inside: a research question, ethics-approved study, honest reporting, and a published standard that institutions then adopt to make every operation safer.

Research ethics is governed worldwide by the same Helsinki principles, but the mechanisms differ by jurisdiction. Examiners accept either system if the principles are right; the comparison below sets the major ones side by side.

The variation is procedural, not moral. Everywhere, the committee must be independent of the researcher, the protocol must show a favourable risk-benefit balance, and the participant's interests prevail over science and society. Professional bodies translate these into surgeon-specific duties: the AAOS Code of Medical Ethics and Professionalism and its Standards of Professionalism in the United States, and the GMC Good Medical Practice in the United Kingdom, both make research honesty, valid consent and accurate authorship explicit professional obligations. None of these frameworks include, and none should ever be reduced to, country-specific billing or reimbursement item numbers — those are irrelevant both to the ethics and to the exam.

Everything below condenses the topic for revision and viva practice — the high-yield points, the memory hooks, worked vivas, and a one-screen cheat sheet.